Enumeral Biomedical (ENUM) 0.2000 $ENUM
Enumeral Receives Maintenance Fee to Continue License Agreement with Pieris and Enters into Definitive License Agreement
BusinessWire - Mon Jun 06, 5:30AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) ("Enumeral" or the "Company"
, a biotechnology company focused on discovering and developing novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced that, as contemplated in the April 18, 2016 License and Transfer Agreement (the "License Agreement", it has received a $750,000 license maintenance fee from and entered into a Definitive License and Transfer Agreement (the "Definitive Agreement" with Pieris Pharmaceuticals, Inc. and Pieris Pharmaceuticals GmbH (collectively, "Pieris" to continue Pieris' license to Enumeral's 388D4 anti-PD-1 antibody.
Enumeral Reports First Quarter Financial Results
BusinessWire - Fri May 13, 3:30PM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) ("Enumeral" or the "Company", a biotechnology company focused on the discovery and development of novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced its financial results for the three months ended March 31, 2016.
Enumeral Announces Additional Data on Its Novel Class of PD-1 Antagonist to be Presented at the American Association for Cancer Research (AACR) 2016 Annual Meeting
BusinessWire - Mon Apr 18, 7:30AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company", a biotechnology company focused on discovering and developing novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced that it will present research findings on the Company's novel class of anti-PD-1 antibodies in a poster at the AACR Annual Meeting 2016 in New Orleans.
Enumeral and Pieris Pharmaceuticals Enter into License and Transfer Agreement
BusinessWire - Mon Apr 18, 5:45AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company", a biotechnology company focused on discovering and developing novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced that it has entered into a License and Transfer Agreement (the "License Agreement" with Pieris Pharmaceuticals, Inc. and Pieris Pharmaceuticals GmbH (collectively, "Pieris".
PIRS: 1.65 (-0.04)
Enumeral to Present at the 3rd Annual Jefferies Immuno-Oncology Summit
BusinessWire - Thu Mar 31, 7:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on the discovery and development of novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced that Arthur H. Tinkelenberg, Ph.D., Enumeral's President and Chief Executive Officer, will present at the 3rd Annual Jefferies Immuno-Oncology Summit at 3:25 pm Eastern Time in the North Atlantic Room of the Boston Harbor Hotel on Thursday, April 7, 2016. The Summit is being held at the Boston Harbor Hotel, Boston Massachusetts, on April 7-8, 2016.
Enumeral Reports Fourth Quarter and Year-End 2015 Financial Results
BusinessWire - Wed Mar 30, 7:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company", a biotechnology company focused on the discovery and development of novel therapeutics that help the immune system fight cancer and other diseases, today announced its financial results for the three months and full year ended December 31, 2015.
Enumeral to Present at the Noble Financial Capital Markets' 12th Annual Investor and Equity Conference
BusinessWire - Tue Jan 19, 7:00AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that Arthur H. Tinkelenberg, Ph.D., Enumeral's President and Chief Executive Officer, will present at the Noble Financial Capital Markets' 12th Annual Investor and Equity Conference on Wednesday, January 20, 2016 at 10:00 am Eastern Time. In addition, Dr. Tinkelenberg will be participating in a panel discussion entitled "The Brave New World of Cancer Immunotherapy" at 5:15 pm Eastern Time on Tuesday, January 19, 2016. The conference is being held at the Club Med in Sandpiper Bay, FL.
Enumeral and MD Anderson Enter Into Collaborative Research and Development Agreement
BusinessWire - Mon Jan 11, 7:00AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) today announced that it has entered into a Collaborative Research and Development Agreement with The University of Texas MD Anderson Cancer Center.
Enumeral Presents Research Results for Novel Class of Anti-PD-1 Antibodies at AACR's 2016 Tumor Microenvironment Special Conference
BusinessWire - Fri Jan 08, 7:00AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company", a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced the presentation of research findings for the Company's novel class of anti-PD-1 antibodies at the Function of the Tumor Microenvironment in Cancer Progression Conference, sponsored by the American Association for Cancer Research (AACR) and taking place in San Diego, CA, from January 7-10, 2016. Enumeral is advancing a novel class of potentially allosteric anti-PD-1 antibodies with distinctive properties compared to currently marketed anti-PD-1 antagonists, including a mechanism of action that does not appear to require the disruption of PD-1 interaction with PD-L1.
Enumeral to Participate in the 2016 East/West CEO Conference
BusinessWire - Wed Jan 06, 7:00AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company", a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that Arthur H. Tinkelenberg, Ph.D., Enumeral's President and Chief Executive Officer, will participate in the 2016 East/West CEO Conference on the panel entitled "Academia and Industry: Challenges and Synergies," on Sunday, January 10, 2016 at 1:30 p.m. Pacific Time. The conference will be held at the Four Seasons Hotel in San Francisco, CA.
Enumeral to Present at Biotech Showcase 2016
BusinessWire - Tue Jan 05, 7:00AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company", a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that Arthur H. Tinkelenberg, Ph.D., Enumeral's President and Chief Executive Officer, will present a corporate overview at Biotech Showcase 2016 on Wednesday, January 13, 2016 at 9:30 a.m. Pacific Time at the Parc 55 Hotel in San Francisco, CA.
Enumeral to Present at the Oppenheimer 26th Annual Healthcare Conference
BusinessWire - Tue Dec 01, 7:00AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company", a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that Arthur H. Tinkelenberg, Ph.D., President and Chief Executive Officer, will present a corporate overview at the Oppenheimer 26th Annual Healthcare Conference on Tuesday, December 8th, 2015 at 3:20 p.m. ET at The Westin New York Grand Central Hotel in New York City.
Enumeral Reports Third Quarter 2015 Financial Results and Provides Corporate Update
BusinessWire - Tue Nov 10, 3:30PM CST
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) ("Enumeral" or the "Company", a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today reported financial results for the quarter ended September 30, 2015.
Enumeral Reports That Its Novel Class of Anti-PD-1 Antibodies Elicits Higher T Cell Activation in Ex Vivo Human Assays than Currently Marketed Anti-PD-1 Antibodies
BusinessWire - Tue Nov 03, 7:00AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced important progress in its anti-PD-1 antibody program. Enumeral researchers have demonstrated greater functional activity of its novel class of anti-PD-1 antibodies (as measured by restoration of T cell function in cell-based assays) when compared to conventional anti-PD-1 antibodies that disrupt PD-1 interaction with PD-L1. Enumeral's potentially allosteric antibodies block PD-L1-mediated immunosuppression, but do not disrupt PD-1 interaction with PD-L1.
Enumeral to Present at the Emerging Concepts in Host Response to Cancer Symposium at The University of Texas MD Anderson Cancer Center
BusinessWire - Mon Oct 05, 7:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that the company will present a poster titled "Human Tumor-Based Identification of Immune Checkpoint Targets" at The University of Texas MD Anderson Cancer Center's Emerging Concepts in Host Response to Cancer Symposium Symposia. Enumeral's poster will highlight recent developments in the company's PD-1 and TIM-3 antibody programs. The poster will be presented at MD Anderson Cancer Center's R. Lee Clark Clinic, 1515 Holcombe Boulevard, Floor 11, in Houston, Texas on October 8, 2015.
Enumeral Announces Identification of Anti-PD-1 Antibodies with Potential for Differentiated Mechanism of Action
BusinessWire - Thu Sep 24, 7:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced important progress in its anti-PD-1 antibody program. Enumeral also provided an update on the progress of additional programs in the Company's R&D pipeline, including its TIM-3 and LAG-3 antibody programs.
Enumeral to Present at the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference and BioPharm America 2015
BusinessWire - Fri Sep 11, 7:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that Enumeral will present a poster titled "Human Tumor-Based Identification of Immune Checkpoint Targets" at the International Cancer Immunotherapy Conference. Enumeral's poster will highlight recent developments in the company's PD-1 and TIM-3 antibody programs. The poster number is B083, and will be presented in the Empire Ballroom at the Sheraton New York Times Square Hotel in New York City from 4:45 pm to 6:45 pm on September 18, 2015.
Enumeral Reports Second Quarter 2015 Financial Results
BusinessWire - Wed Aug 12, 3:30PM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company", a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today reported financial results for the quarter ended June 30, 2015.
Enumeral Appoints Robert J. Easton to its Board of Directors
BusinessWire - Thu Jul 30, 3:30PM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that it has appointed Robert J. Easton to its Board of Directors. Mr. Easton is a recognized leader in the life sciences and healthcare industries, having led strategy development and supervised opportunity assessments for hundreds of clients across the globe, including large and specialty pharmaceutical companies, early-stage and publicly traded biopharmaceutical companies, and diagnostics businesses. Mr. Easton currently serves as Co-Chairman of Bionest Partners, Inc., a consulting firm he co-founded that specializes in strategic planning for pharmaceutical, medical device and diagnostic companies.
Enumeral Announces Progress in PD-1, TIM-3 and Other Pipeline Programs
BusinessWire - Tue Jul 14, 7:45AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced recent progress in its PD-1 antibody program. Enumeral also provided an update on the progress of additional programs in the Company's R&D pipeline, including its TIM-3 antibody program.
Enumeral Receives Maintenance Fee to Continue License Agreement with Pieris and Enters into Definitive License Agreement
BusinessWire - Mon Jun 06, 5:30AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) ("Enumeral" or the "Company"
, a biotechnology company focused on discovering and developing novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced that, as contemplated in the April 18, 2016 License and Transfer Agreement (the "License Agreement", it has received a $750,000 license maintenance fee from and entered into a Definitive License and Transfer Agreement (the "Definitive Agreement" with Pieris Pharmaceuticals, Inc. and Pieris Pharmaceuticals GmbH (collectively, "Pieris" to continue Pieris' license to Enumeral's 388D4 anti-PD-1 antibody. Enumeral Reports First Quarter Financial Results
BusinessWire - Fri May 13, 3:30PM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) ("Enumeral" or the "Company"
, a biotechnology company focused on the discovery and development of novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced its financial results for the three months ended March 31, 2016. Enumeral Announces Additional Data on Its Novel Class of PD-1 Antagonist to be Presented at the American Association for Cancer Research (AACR) 2016 Annual Meeting
BusinessWire - Mon Apr 18, 7:30AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company"
, a biotechnology company focused on discovering and developing novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced that it will present research findings on the Company's novel class of anti-PD-1 antibodies in a poster at the AACR Annual Meeting 2016 in New Orleans. Enumeral and Pieris Pharmaceuticals Enter into License and Transfer Agreement
BusinessWire - Mon Apr 18, 5:45AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company"
, a biotechnology company focused on discovering and developing novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced that it has entered into a License and Transfer Agreement (the "License Agreement" with Pieris Pharmaceuticals, Inc. and Pieris Pharmaceuticals GmbH (collectively, "Pieris". PIRS: 1.65 (-0.04)
Enumeral to Present at the 3rd Annual Jefferies Immuno-Oncology Summit
BusinessWire - Thu Mar 31, 7:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on the discovery and development of novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced that Arthur H. Tinkelenberg, Ph.D., Enumeral's President and Chief Executive Officer, will present at the 3rd Annual Jefferies Immuno-Oncology Summit at 3:25 pm Eastern Time in the North Atlantic Room of the Boston Harbor Hotel on Thursday, April 7, 2016. The Summit is being held at the Boston Harbor Hotel, Boston Massachusetts, on April 7-8, 2016.
Enumeral Reports Fourth Quarter and Year-End 2015 Financial Results
BusinessWire - Wed Mar 30, 7:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company"
, a biotechnology company focused on the discovery and development of novel therapeutics that help the immune system fight cancer and other diseases, today announced its financial results for the three months and full year ended December 31, 2015. Enumeral to Present at the Noble Financial Capital Markets' 12th Annual Investor and Equity Conference
BusinessWire - Tue Jan 19, 7:00AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that Arthur H. Tinkelenberg, Ph.D., Enumeral's President and Chief Executive Officer, will present at the Noble Financial Capital Markets' 12th Annual Investor and Equity Conference on Wednesday, January 20, 2016 at 10:00 am Eastern Time. In addition, Dr. Tinkelenberg will be participating in a panel discussion entitled "The Brave New World of Cancer Immunotherapy" at 5:15 pm Eastern Time on Tuesday, January 19, 2016. The conference is being held at the Club Med in Sandpiper Bay, FL.
Enumeral and MD Anderson Enter Into Collaborative Research and Development Agreement
BusinessWire - Mon Jan 11, 7:00AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) today announced that it has entered into a Collaborative Research and Development Agreement with The University of Texas MD Anderson Cancer Center.
Enumeral Presents Research Results for Novel Class of Anti-PD-1 Antibodies at AACR's 2016 Tumor Microenvironment Special Conference
BusinessWire - Fri Jan 08, 7:00AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company"
, a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced the presentation of research findings for the Company's novel class of anti-PD-1 antibodies at the Function of the Tumor Microenvironment in Cancer Progression Conference, sponsored by the American Association for Cancer Research (AACR) and taking place in San Diego, CA, from January 7-10, 2016. Enumeral is advancing a novel class of potentially allosteric anti-PD-1 antibodies with distinctive properties compared to currently marketed anti-PD-1 antagonists, including a mechanism of action that does not appear to require the disruption of PD-1 interaction with PD-L1. Enumeral to Participate in the 2016 East/West CEO Conference
BusinessWire - Wed Jan 06, 7:00AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company"
, a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that Arthur H. Tinkelenberg, Ph.D., Enumeral's President and Chief Executive Officer, will participate in the 2016 East/West CEO Conference on the panel entitled "Academia and Industry: Challenges and Synergies," on Sunday, January 10, 2016 at 1:30 p.m. Pacific Time. The conference will be held at the Four Seasons Hotel in San Francisco, CA. Enumeral to Present at Biotech Showcase 2016
BusinessWire - Tue Jan 05, 7:00AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company"
, a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that Arthur H. Tinkelenberg, Ph.D., Enumeral's President and Chief Executive Officer, will present a corporate overview at Biotech Showcase 2016 on Wednesday, January 13, 2016 at 9:30 a.m. Pacific Time at the Parc 55 Hotel in San Francisco, CA. Enumeral to Present at the Oppenheimer 26th Annual Healthcare Conference
BusinessWire - Tue Dec 01, 7:00AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company"
, a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that Arthur H. Tinkelenberg, Ph.D., President and Chief Executive Officer, will present a corporate overview at the Oppenheimer 26th Annual Healthcare Conference on Tuesday, December 8th, 2015 at 3:20 p.m. ET at The Westin New York Grand Central Hotel in New York City. Enumeral Reports Third Quarter 2015 Financial Results and Provides Corporate Update
BusinessWire - Tue Nov 10, 3:30PM CST
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) ("Enumeral" or the "Company"
, a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today reported financial results for the quarter ended September 30, 2015. Enumeral Reports That Its Novel Class of Anti-PD-1 Antibodies Elicits Higher T Cell Activation in Ex Vivo Human Assays than Currently Marketed Anti-PD-1 Antibodies
BusinessWire - Tue Nov 03, 7:00AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced important progress in its anti-PD-1 antibody program. Enumeral researchers have demonstrated greater functional activity of its novel class of anti-PD-1 antibodies (as measured by restoration of T cell function in cell-based assays) when compared to conventional anti-PD-1 antibodies that disrupt PD-1 interaction with PD-L1. Enumeral's potentially allosteric antibodies block PD-L1-mediated immunosuppression, but do not disrupt PD-1 interaction with PD-L1.
Enumeral to Present at the Emerging Concepts in Host Response to Cancer Symposium at The University of Texas MD Anderson Cancer Center
BusinessWire - Mon Oct 05, 7:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that the company will present a poster titled "Human Tumor-Based Identification of Immune Checkpoint Targets" at The University of Texas MD Anderson Cancer Center's Emerging Concepts in Host Response to Cancer Symposium Symposia. Enumeral's poster will highlight recent developments in the company's PD-1 and TIM-3 antibody programs. The poster will be presented at MD Anderson Cancer Center's R. Lee Clark Clinic, 1515 Holcombe Boulevard, Floor 11, in Houston, Texas on October 8, 2015.
Enumeral Announces Identification of Anti-PD-1 Antibodies with Potential for Differentiated Mechanism of Action
BusinessWire - Thu Sep 24, 7:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced important progress in its anti-PD-1 antibody program. Enumeral also provided an update on the progress of additional programs in the Company's R&D pipeline, including its TIM-3 and LAG-3 antibody programs.
Enumeral to Present at the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference and BioPharm America 2015
BusinessWire - Fri Sep 11, 7:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that Enumeral will present a poster titled "Human Tumor-Based Identification of Immune Checkpoint Targets" at the International Cancer Immunotherapy Conference. Enumeral's poster will highlight recent developments in the company's PD-1 and TIM-3 antibody programs. The poster number is B083, and will be presented in the Empire Ballroom at the Sheraton New York Times Square Hotel in New York City from 4:45 pm to 6:45 pm on September 18, 2015.
Enumeral Reports Second Quarter 2015 Financial Results
BusinessWire - Wed Aug 12, 3:30PM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company"
, a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today reported financial results for the quarter ended June 30, 2015. Enumeral Appoints Robert J. Easton to its Board of Directors
BusinessWire - Thu Jul 30, 3:30PM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that it has appointed Robert J. Easton to its Board of Directors. Mr. Easton is a recognized leader in the life sciences and healthcare industries, having led strategy development and supervised opportunity assessments for hundreds of clients across the globe, including large and specialty pharmaceutical companies, early-stage and publicly traded biopharmaceutical companies, and diagnostics businesses. Mr. Easton currently serves as Co-Chairman of Bionest Partners, Inc., a consulting firm he co-founded that specializes in strategic planning for pharmaceutical, medical device and diagnostic companies.
Enumeral Announces Progress in PD-1, TIM-3 and Other Pipeline Programs
BusinessWire - Tue Jul 14, 7:45AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced recent progress in its PD-1 antibody program. Enumeral also provided an update on the progress of additional programs in the Company's R&D pipeline, including its TIM-3 antibody program.
